Bu-Sn

Bu-Sn (also known as Bu2SnL) is a novel dibutyl organotin(IV) complex containing a multifunctional benzyl 2-(diphenylphosphoryl)hydrazine-1-carbodithioate ligand. Developed by researchers at the University of Iceland, Bu-Sn is being investigated as an alternative to platinum-based chemotherapeutics like cisplatin. It exhibits potent in vitro cytotoxic activity against various cancer cell lines, particularly breast carcinoma (T-47D), colorectal carcinoma (HCT116), and pancreatic adenocarcinoma (AsPC-1), while demonstrating minimal toxicity toward non-tumorigenic cells. Mechanistically, Bu-Sn accumulates preferentially in the cell nucleus, where it targets DNA to induce pronounced genotoxic stress, double-strand DNA breaks, G1-phase cell cycle arrest, and intracellular ATP depletion, ultimately triggering apoptotic cell death.

Other names

dibutyltin(IV) benzyl 2-(diphenylphosphoryl)hydrazine-1-carbodithioate